


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) Compounds of the formula I



in which

$R^2$ ,  $R^4$  denote H, A, Hal, cycloalkyl having 3 to 7 C atoms,  $CF_3$ ,  $NO_2$ , CN,  $OCF_3$ , OA, NHA,  $NA_2$ ,  $NH_2$ ,

$R^3$ ,  $R^6$  denote  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar,

$R^1$  denotes H or ~~an organic radical, in particular~~  
 $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCOHet$ , CHO,  $(CH_2)_nOR^5$ ,  $(CH_2)_nHet$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  
 $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_n(R^5)Het$ ,  $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nOCOR'$ ,  
 $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)OCOR^5$ ,  
 $(CH_2)_nN(R')CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  
 $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCOOR^5$ ,  
 $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$   
 or  $(CH_2)_nN(R^5)Ar$ ,

$R^5$  denotes H or A

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic ~~or linear~~  
~~or branched~~ organic radical

containing one or more hetero atoms which is unsubstituted or mono- or  
polysubstituted by A and/or Hal,

Ar denotes a phenyl radical which is unsubstituted or mono or polysubstituted by  
A and/or Hal, OR<sup>5</sup>, OOCR<sup>5</sup>, COOR<sup>5</sup>,  
CON(R<sup>5</sup>)<sub>2</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, NHCOR<sup>5</sup>, CF<sub>3</sub> or SO<sub>2</sub>CH<sub>3</sub>,

X denotes CH or N,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I

where, in the case that X has the meaning CH, R<sup>2</sup> and R<sup>4</sup> do not simultaneously  
denote H,

or salts, ~~solvates~~, enantiomers, racemates thereof or mixtures of enantiomers.

2. (Original) Compounds of the formula I according to Claim 1, in which R<sup>6</sup>  
denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-,  
ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-,  
dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl,  
thiophen-2-yl or thiophen-3-yl.







3. (Previously Presented) Compounds of the formula I according to claim 1, in  
which R<sup>4</sup> denotes H, Hal, CN, A or NO<sub>2</sub>.

4. (Previously Presented) Compounds of the formula I according to claim 1, in  
which R<sup>2</sup> denotes H or alkyl.

5. (Previously Presented) Compounds of the formula I according to claim 1, in which R<sup>3</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl.

6. (Previously Presented) Compounds of the formula I according to claim 1, in which X has the meaning N.


7. (Original) Compounds of the formulae IA, IB, IC, ID, IE and IF:




in which

$R^3$ ,  $R^4$ ,  $R^6$  and X have the meanings indicated in Claim 1.

8. (Previously Presented) Process for the preparation of compounds of the formula IA




in which  $R^3$ ,  $R^4$ ,  $R^6$ , X and A have the meaning indicated in Claim 1 or salts or solvates thereof, comprising reacting a compound of the formula II



or acid-addition salts thereof in which

$R^4$ ,  $R^6$  and X have the meanings indicated in Claim 1, with a compound of the formula III




in which


A and  $R^3$  have the meanings indicated in Claim 1,

and/or converting a basic compound of the formula IA into one of its salts by treatment with an acid.

9. (Previously Presented) Process for the preparation of compounds of the formula IB




in which R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup>, X and A have the meaning indicated in Claim 1 or salts or solvates thereof, comprising reacting a compound of the formula II



or acid-addition salts thereof in which

R<sup>4</sup>, R<sup>6</sup> and X have the meanings indicated in Claim 1, with a compound of the formula IV



in which

A and R<sup>3</sup> have the meanings indicated in Claim 1,

and/or converting a basic compound of the formula IB into one of its salts by treatment with an acid.

10. (Cancelled)

11. (Currently Amended) A method for the treatment or prophylaxis of ~~diseases~~ sleep

disorders mediated by the binding of ~~the~~ compounds I to 5 HT receptors, comprising administering to a host in need thereof a compound, salt, ~~solvate~~, enantiomer, racemate or enantiomer mixture of claim 1.

12. (Cancelled)


13. (Currently Amended) A method according to claim 11, wherein the salt, ~~solvate~~, enantiomer, racemate or enantiomer mixture has a 5-HT<sub>2A</sub> receptor-antagonistic action.

14. (Currently Amended) A pharmaceutical composition comprising at least one compound of the formula I according to claim 1 and/or one of its physiologically acceptable salts ~~and/or one of its solvates~~, and a pharmaceutically acceptable carrier.

15. (Currently Amended) A process for the preparation of a pharmaceutical composition, comprising combining a compound of the formula I according to Claim 1 and/or one of its physiological acceptable salts ~~and/or one of its solvates~~ into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

16. (Currently Amended) A method for the prophylaxis ~~and/or treatment of psychoses, neurological disorders, amyotrophic lateral sclerosis, eating disorders,~~ premenstrual syndrome ~~and/or for positively influencing obsessive compulsive disorder (OCD),~~ comprising administering to a host in need thereof a compound, salt, ~~solvate~~, enantiomer, racemate or ~~enantiomer~~ enantiomer mixture of claim 1.

17. (Currently Amended) Compounds of formula I according to claim 1 in which Het denotes one of the following radicals:




---

18. (New) A method for the prophylaxis or treatment of schizophrenia or depression, comprising administering to a host in need thereof a compound, salt, enantiomer, racemate or enantiomer mixture of claim 1.